EMA Application withdrawn: Bosatria (Mepolizumab) — Glaxo Group Limited

View source ↗

Summary

The EMA withdrew the application for Bosatria (mepolizumab) by Glaxo Group Limited for hypereosinophilic syndrome.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypereosinophilic Syndrome

Drugs mentioned

• Bosatria (mepolizumab)

Snippet

Status: Application withdrawn. Therapeutic area: Hypereosinophilic Syndrome. MAH: Glaxo Group Limited. Decision date: 31/12/2009. Orphan medicine